Covalent and non-covalent reversible proteasome inhibition

Biological Chemistry

Volumn 393, Issue 10, 2012, Pages 1101-1120

  Beck, Philipp ^a   Dubiella, Christian ^a   Groll, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Drug development; Inhibitor; Non covalent; Reversible; Ubiquitin pathway

Indexed keywords

ALDEHYDE; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPAIN; CARFILZOMIB; CYCLOPEPTIDE; DELANZOMIB; FATTY ACID; GAMMA INTERFERON; HYDROXYUREA; LACTACYSTIN; LACTONE DERIVATIVE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL PRODUCT; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING SITE; CANCER THERAPY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENTHALPY; ENTROPY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EUKARYOTIC CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROLYSIS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENTROPY; HUMANS; MOLECULAR TARGETED THERAPY; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EUKARYOTA;

EID: 84869464416     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0212     Document Type: Article

References (111)

1. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A, Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.-T., Plamondon, L., and Stein, R.L. (1998). Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338.
2. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., and Elliott, P.J. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents proteasome inhibitors. Cancer Res. 59, 2615-2622.
3. Albrecht, B.K. and Williams, R.M. (2004). A concise, total synthesis of the TMC-95A/B proteasome inhibitors. PNAS 101, 11949-11954.
4. André, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B.L., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., and Lotteau, V. (1998). An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. PNAS 95, 13120-13124.
5. Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J., et al. (2011). Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17, 2734-2743.
6. Asai, A., Hasegawa, A., Ochiai, K., Yamashita, Y., and Mizukami, T. (2000). Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J. Antibiot. (Tokyo). 53, 81-83.
7. Asai, A., Tsujita, T., Sharma, S.V., Yamashita, Y., Akinaga, S., Funakoshi, M., Kobayashi, H., and Mizukami, T. (2004). A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Bioche. Pharmacol. 67, 227-234.
8. Basler, M., Dajee, M., Moll, C., Groettrup, M., and Kirk, C.J. (2010). Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J. Immunol. 185, 634-641.
9. Basse, N., Piguel, S., Papapostolou, D., Ferrier-Berthelot, A., Richy, N., Pagano, M., Sarthou, P., Sobczak-Thépot, J., Reboud-Ravaux, M., and Vidal, J. (2007). Linear TMC-95-based proteasome inhibitors. J. Med. Chem. 50, 2842-2850.
10. Ben-Shem, A., Jenner, L., Yusupova, G., and Yusupov, M. (2010). Crystal structure of the eukaryotic ribosome. Science 330, 1203-1209.
11. Berkers, C.R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B.M., Anderson, K.C., Ploegh, H.L., Ovaa, H., and Galardy, P.J. (2005). Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2, 357-362.
12. Berthelot, A., Piguel, S., Le Dour, G., and Vidal, J. (2003). Synthesis of macrocyclic peptide analogues of proteasome inhibitor TMC-95A. J. Organic Chem. 68, 9835-9838.
13. Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., et al. (2009). The proteasome load vs. capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113, 3040-3049.
14. Blackburn, C., Gigstad, K.M., Hales, P., Garcia, K., Jones, M., Bruzzese, F.J., Barrett, C., Liu, J.X., Soucy, T.A., Sappal, D.S., et al. (2010). Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem. J. 430, 461-476.
15. Bochtler, M., Ditzel, L., Groll, M., Hartmann, C., and Huber, R. (1999). The proteasome. Ann. Rev. Biophys. Biomol. Struct. 28, 295-317.
16. Borissenko, L. and Groll, M. (2007). 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107, 687-717.
17. Brannigan, J.A., Dodson, H.J., Moody, P.C.E., Smith, J.L., Tomchick, D.R., and Murzin, A.G. (1995). A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature 378, 416-419.
18. Braun, H.A., Umbreen, S., Groll, M., Kuckelkorn, U., Mlynarczuk, I., Wigand, M.E., Drung, I., Kloetzel, P.-M., and Schmidt, B. (2005). Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem.y 280, 28394-28401.
19. Bross, P., Farrell, A., and Pazdur, R. (2003). Velcade(R): U.S. FDA Approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513.
20. Burgi, H., Dunitz, J., and Shefter, E. (1973). Geometrical reaction coordinates. II. Nucleophilic addition to a carbonyl group. J. Am. Chem. Soc. 587, 5065-5067.
21. Cascio, P., Call, M., Petre, B.M., Walz, T., and Goldberg, A.L. (2002). Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J. 21, 2636-2645.
22. Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8, 407-419.
23. Chauhan, D., Singh, A.V., Aujay, M., Kirk, C.J., Bandi, M., Ciccarelli, B., Raje, N., Richardson, P., and Anderson, K. C. (2010). A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116, 4906-4915.
24. Chauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., and Anderson, K.C. (2011). In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Caner Res. 17, 5311-5321.
25. Craiu, A., Gaczynska, M., Akopian, T., Gramm, C.F., Fenteany, G., Goldberg, A.L., and Rock, K.L. (1997). Lactacystin and clastolactacystin β -lactone modify multiple proteasome β -subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272, 13437-13445.
26. Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., et al. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383-6391.
27. Dick, L.R., Cruikshank, A.A., Destree, A.T., Grenier, L., McCormack, T.A., Melandri, F.D., Nunes, S.L., Palombella, V.J., Parent, L.A., Plamondon, L., et al. (1997). Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272, 182-188.
28. Dorsey, B.D., Iqbal, M., Chatterjee, S., Menta, E., Bernardini, R., Bernareggi, A., Cassarà, P.G., D' Arasmo, G., Ferretti, E., De Munari, S., et al. (2008). Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J. Med. Chem. 51, 1068-1072.
29. Driscoll, J., Brown, M., and Finley, D. (1993). MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365, 262-264.
30. Feling, R.H., Buchanan, G.O., Mincer, T.J., Kauffman, C.A., Jensen, P.R., and Fenical, W. (2003). Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl. 42, 355-357.
31. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J., and Schreiber, S.L. (1995). Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731.
32. Figueiredo-Pereira, M.E., Berg, K.A., and Wilk, S. (1994). A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63, 1578-1581.
33. Franke, N.E., Niewerth, D., Assaraf, Y.G., van Meerloo, J., Vojtekova, K., van Zantwijk, C.H., Zweegman, S., Chan, E.T., Kirk, C.J., Geerke, D.P., et al. (2012). Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26, 757-768.
34. Furet, P., Imbach, P., Noorani, M., Koeppler, J., Laumen, K., Lang, M., Guagnano, V., Fuerst, P., Roesel, J., Zimmermann, J., et al. (2004). Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J. Med. Chem. 47, 4810-4813.
35. Gallastegui, N. and Groll, M. (2010). The 26S proteasome: assembly and function of a destructive machine. Trends Biochem. Sci. 35, 634-642.
36. Gallastegui, N., Beck, P., Arciniega, M., Huber, R., Hillebrand, S., and Groll, M. (2012). Hydroxyureas as noncovalent proteasome inhibitors. Angew. Chem. Int. Ed. Engl. 51, 247-249.
37. Ge, Y., Kazi, A., Marsilio, F., Luo, Y., Jain, S., Brooks, W., Daniel, K.G., Guida, W.C., Sebti, S.M., and Lawrence, H.R. (2012). Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J. Med. Chem. 55, 1978-1998.
38. Groettrup, M., Kraft, R., Kostka, S., Standera, S., Stohwasser, R., and Kloetzel, P.-M. (1996). A third interferon-γ-induced subunit exchange in the 20S proteasome. Eur. J. Immunol. 26, 863-869.
39. Groll, M. and Huber, R. (2003). Substrate access and processing by the 20S proteasome core particle. Int. J. Biochem. Cell Biol. 35, 606-616.
40. Groll, M. and Potts, B.C. (2011). Proteasome structure, function, and lessons learned from β -lactone inhibitors. Curr. Top. Med. Chem. 11, 2850-2878.
41. Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, H.D., and Huber, R. (1997). Structure of 20S proteasome from yeast at 2.4 resolution. Nature 386, 463-471.
42. Groll, M., Kim, K.B., Kairies, N., Huber, R., and Crews, C. M. (2000). Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′, β′-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122, 1237-1238.
43. Groll, M., Koguchi, Y., Huber, R., and Kohno, J. (2001). Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol. 311, 543-548.
44. Groll, M., Nazif, T., Huber, R., and Bogyo, M. (2002). Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chem. Biol. 9, 655-662.
45. Groll, M., Berkers, C.R., Ploegh, H.L., and Ovaa, H. (2006a). Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14, 451-456.
46. Groll, M., Gotz, M., Kaiser, M., Weyher, R., and Moroder, L. (2006b). TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 13, 607-614.
47. Groll, M., Huber, R., and Potts, B.C.M. (2006c). Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β -lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 128, 5136-5141.
48. Groll, M., Larionov, O. V., Huber, R., and de Meijere, A. (2006d). Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. PNAS 103, 4576-4579.
49. Groll, M., Schellenberg, B., Bachmann, A.S., Archer, C.R., Huber, R., Powell, T.K., Lindow, S., Kaiser, M., and Dudler, R. (2008). A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 452, 755-758.
50. Groll, M., Huber, R., and Moroder, L. (2009). The persisting challenge of selective and specific proteasome inhibition. J. Peptide Sci. 15, 58-66.
51. Groll, M., Gallastegui, N., Maréhal, X., Le Ravalec, V., Basse, N., Richy, N., Genin, E., Huber, R., Moroder, L., Vidal, J., et al. (2010). 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A. Chem. Med. Chem. 5, 1701-1705.
52. Grawert, M.A., Gallastegui, N., Stein, M., Schmidt, B., Kloetzel, P.-M., Huber, R., and Groll, M. (2011). Elucidation of the β -keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition. Angew. Chem. Int. Ed. Engl. 50, 542-544.
53. Hanada, M., Sugawara, K., Kaneta, K., Toda, S., Nishiyama, Y., Tomita, K., Yamamoto, H., Konishi, M., and Oki, T. (1992). Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. (Tokyo). 45, 1746-1752.
54. Harding, C.V., France, J., Song, R., Farah, J.M., Chatterjee, S., and Chester, W. (1995). Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J. immunol. 155, 1767-1775.
55. Hershko, A. and Ciechanover, A. (1998). The ubiquitin system. Ann. Rev. Biochem. 67, 425-479.
56. Hines, J., Groll, M., Fahnestock, M., and Crews, C. M. (2008). Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem. Biol. 15, 501-512.
57. Huber, E.M. and Groll, M. (2012). Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development. Angew. Chem. Int. Ed. Engl. 51, 8708-8720.
58. Huber, E.M., Basler, M., Schwab, R., Heinemeyer, W., Kirk, C.J., Groettrup, M., and Groll, M. (2012). Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148, 727-738.
59. Ichikawa, H.T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B.I., Kirk, C.J., et al. (2011). Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum. 64, 493-503.
60. Kaiser, M., Groll, M., Renner, C., Huber, R., and Moroder, L. (2002). The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem. Int. Ed. Engl. 41, 780- 783.
61. Kaiser, M., Siciliano, C., Assfalg-Machleidt, I., Groll, M., Milbradt, A.G., and Moroder, L. (2003). Synthesis of a TMC-95A ketomethylene analogue by cyclization via intramolecular Suzuki coupling. Org. Lett. 5, 3435-3437.
62. Kaiser, M., Groll, M., Siciliano, C., Assfalg-Machleidt, I., Weyher, E., Kohno, J., Milbradt, A.G., Renner, C., Huber, R., and Moroder, L. (2004a). Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. Chem. Bio. Chem. 5, 1256-1266.
63. Kaiser, M., Milbradt, A., Siciliano, C., Assfalg-Machleidt, I., Machleidt, W., Groll, M., Renner, C., and Moroder, L. (2004b). TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors. Chem. Biodivers. 1, 161-173.
64. Kane, R.C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., and Pazdur, R. (2007). Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 13, 5291-5294.
65. Kazi, A., Lawrence, H., Guida, W.C., McLaughlin, M.L., Springett, G.M., Berndt, N., Yip, R.M.L., and Sebti, S.M. (2009). Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 8, 1940-1951.
66. Kisselev, A.F. and Goldberg, A.L. (2001). Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758.
67. Klebe, G. (2011). On the validity of popular assumptions in computational drug design. J. Cheminform. 3, O18.
68. Koguchi, Y., Kohno, J., Nishio, M., Takagashi, K., Okuda, T., Ohnuki, T., and Komatsubara, S. (2000). TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J. Antibiot. (Tokyo). 53, 105-109.
69. Korotkov, V.S., Ludwig, A., Larionov, O.V., Lygin, A.V., Groll, M., and de Meijere, A. (2011). Synthesis and biological activity of optimized belactosin C congeners. Org. Biomol. Chem. 9, 7791-7798.
70. Krunic, A., Vallat, A., Mo, S., Lantvit, D.D., Swanson, S.M., and Orjala, J. (2010). Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii. J. Nat. Prod. 73, 1927- 1932.
71. Kuhn, D., Orlowski, R., and Bjorklund, C. (2011). Second generation proteasome inhibitors: Carfilzomib and immunoproteasomespecific inhibitors (IPSIs). Curr. Cancer Drug Targets 11, 285-295.
72. Kumar, S.K., Lee, J.H., Lahuerta, J.J., Morgan, G., Richardson, P.G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012). Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149-157.
73. Kupperman, E., Lee, E.C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010). Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980.
74. Lawrence, H.R., Kazi, A., Luo, Y., Kendig, R., Ge, Y., Jain, S., Daniel, K., Santiago, D., Guida, W.C., and Sebti, S.M. (2010). Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg. Med. Chem. 18, 5576- 5592.
75. Ley, S.V., Priour, A., and Heusser, C. (2002). Total synthesis of the cyclic heptapeptide Argyrin B: a new potent inhibitor of T-cell independent antibody formation. Org. Lett. 4, 711-714.
76. Lin, S. and Danishefsky, S.J. (2002). The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides. Angew. Chem. Int. Ed. Engl. 41, 512-515.
77. Lin, S., Yang, Z.-Q., Kwok, B.H.B., Koldobskiy, M., Crews, C.M., and Danishefsky, S.J. (2004). Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. J. Am. Chem. Soc. 126, 6347-6355.
78. Lin, G., Li, D., de Carvalho, L.P.S., Deng, H., Tao, H., Vogt, G., Wu, K., Schneider, J., Chidawanyika, T., Warren, J.D., et al. (2009). Inhibitors selective for mycobacterial versus. human proteasomes. Nature 461, 621-626.
79. Loidl, G., Groll, M., Musiol, H.J., Ditzel, L., Huber, R., and Moroder, L. (1999a). Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol. 6, 197-204.
80. Loidl, G., Groll, M., Musiol, H.J., Huber, R., and Moroder, L. (1999b). Bivalency as a principle for proteasome inhibition. PNAS 96, 5418-5422.
81. Lowe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W., and Huber, R. (1995). Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 268, 533 -53 9.
82. Lum, R.T., Nelson, M.G., Joly, A., Horsma, A.G., Lee, G., Meyer, S.M., Wick, M.M., and Schow, S.R. (1998). Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg. Med. Chem. Lett. 8, 209-214.
83. Lynas, J.F., Harriott, P., Healy, A., McKervey, M.A., and Walker, B. (1998). Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl α -keto aldehydes (glyoxals). Bioorg. Med. Chem. Lett. 8, 373-378.
84. Macherla, V.R., Mitchell, S.S., Manam, R.R., Reed, K.A., Chao, T.H., Nicholson, B., Deyanat-Yazdi, G., Mai, B., Jensen, P.R., Fenical, W.F., et al. (2005). Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem. 48, 3684-3687.
85. Maldonado, L.A., Fenical, W., Jensen, P.R., Kauffman, C.A., Mincer, T.J., Ward, A.C., Bull, A.T., and Goodfellow, M. (2005). Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int. J. System. Evol. Microbiol. 55, 1759-1766.
86. Manam, R.R., McArthur, K.A., Chao, T.-H., Weiss, J., Ali, J.A., Palombella, V.J., Groll, M., Lloyd, G.K., Palladino, M.A., Neuteboom, S.T.C., et al. (2008). Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J. Med. Chem. 51, 6711-6724.
87. Meng, L., Mohan, R., Kwok, B.H.B., Elofsson, M., Sin, N., and Crews, C.M. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. PNAS 96, 10403-10408.
88. Momose, I., Sekizawa, R., Hirosawa, S., Ikeda, D., Naganawa, H., Iinuma, H., and Takeuchi, T. (2001). Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. II. Structure determination and synthesis. J. Antibiot. (Tokyo). 54, 1004-1012.
89. Momose, I., Umezawa, Y., Hirosawa, S., Iijima, M., Iinuma, H., and Ikeda, D. (2005). Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Biosci. Biotech. Biochem. 69, 1733-1742.
90. Muchamuel, T., Basler, M., Aujay, M.A., Suzuki, E., Kalim, K.W., Lauer, C., Sylvain, C., Ring, E.R., Shields, J., Jiang, J., et al. (2009). A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 15, 781-787.
91. Murata, S., Sasaki, K., Kishimoto, T., Niwa, S.-I., Hayashi, H., Takahama, Y., and Tanaka, K. (2007). Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 316, 1349-1353.
92. Nawrocki, S.T., Carew, J.S., Dunner, K., Boise, L.H., Chiao, P.J., Huang, P., Abbruzzese, J.L., and McConkey, D.J. (2005). Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65, 11510-11519.
93. Nazif, T. and Bogyo, M. (2001). Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. PNAS 98, 2967-2972.
94. Nickeleit, I., Zender, S., Sasse, F., Geffers, R., Brandes, G., Sorensen, I., Steinmetz, H., Kubicka, S., Carlomagno, T., Menche, D., et al. (2008). Argyrin A reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14, 23-35.
95. Nussbaum, A.K., Dick, T.P., Keilholz, W., Schirle, M., Stevanovič, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D.H., Huber, R., et al. (1998). Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1. PNAS 95, 12504-12509.
96. Orlowski, M., Cardozo, C., and Michaud, C. (1993). Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32, 1563-1572.
97. Palombella, V.J., Rando, O.J., Goldberg, A.L., and Maniatis, T. (1994). The ubiquitin-proteasome pathway is required for processing the NF- κ B1 precursor protein and the activation of NF- κ B. Cell 78, 773-785.
98. Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., et al. (2008). CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111, 2765-2775.
99. Prudhomme, J., McDaniel, E., Ponts, N., Bertani, S., Fenical, W., Jensen, P., and Le Roch, K. (2008). Marine actinomycetes: a new source of compounds against the human malaria parasite. PloS ONE 3, e2335.
100. Rammensee, H.-G., Friede, T., and Stevanovic, S. (1995). MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228.
101. Rock, K.L. and Goldberg, A.L. (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. Ann. Rev. Immunol. 17, 739-779.
102. Rydzewski, R.M., Burrill, L., Mendonca, R., Palmer, J.T., Rice, M., Tahilramani, R., Bass, K.E., Leung, L., Gjerstad, E., Janc, J.W., et al. (2006). Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. J. Med. Chem. 49, 2953-2968.
103. Schmidtke, G., Kraft, R., Kostka, S., Henklein, P., Frommel, C., Lowe, J., Huber, R., Kloetzel, P.M., and Schmidt, M. (1996). Analysis of mammalian 20S proteasome biogenesis: the maturation of β -subunits is an ordered two-step mechanism involving autocatalysis. EMBO J. 15, 6887-6898.
104. Schmidtke, G., Holzhu, H.-G., Bogyo, M., Kairies, N., Groll, M., Giuli, R. D., Emch, S., and Groettrup, M. (1999). How an inhibitor of the HIV-I protease modulates proteasome activity. Biochemistry 274, 35734-35740.
105. Seemuller, E., Lupas, A., Stock, D., Lowe, J., Huber, R., and Baumeister, W. (1995). Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268, 579-582.
106. Sun, J., Nam, S., Lee, C.-S., and Sebti, S.M. (2001). CEP1612, a dipeptidyl proteasome inhibitor, induces p21 WAF1 and p27 KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 15, 1280-1284.
107. Vinitsky, A., Michaud, C., Powers, J.C., and Orlowski, M. (1992). Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31, 9421- 9428.
108. Voorhees, P.M., Dees, E.C., Neil, B.O., and Orlowski, R.Z. (2003). The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316-6325.
109. Wilk, S. and Orlowski, M. (1983). Evidence that pituitary cationsensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. 40, 842-849.
110. Yang, Z.-Q., Kwok, B.H.B., Lin, S., Koldobskiy, M.A., Crews, C.M., and Danishefsky, S.J. (2003). Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. Chem. Bio. Chem. 4, 508-513.
111. Zhou, H.-J., Aujay, M.A., Bennett, M.K., Dajee, M., Demo, S.D., Fang, Y., Ho, M.N., Jiang, J., Kirk, C.J., Laidig, G.J., et al. (2009). Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52, 3028-3038.